
Kite Acquires Interius BioTherapeutics to Expand In Vivo CAR Technology Portfolio
Kite, a subsidiary of Gilead Sciences (Nasdaq: GILD), has made a significant move in the biotechnology sector by acquiring Interius BioTherapeutics for $350 million in cash. This strategic acquisition aims to integrate in vivo chimeric antigen receptor (CAR) technology into Kite’s existing cell therapy offerings, marking a pivotal step toward more accessible and scalable treatment options for patients.
Interius BioTherapeutics has developed a groundbreaking platform that enables the generation of CAR T-cells directly within the patient's body through a single intravenous infusion. Unlike traditional ex vivo CAR T therapies, which require harvesting, engineering, and reinfusing cells—often accompanied by preconditioning chemotherapy—Interius’s approach involves inserting therapeutic DNA directly into the patient’s genome. This method is designed to deliver long-lasting effects while eliminating several complex steps in the treatment process.
The company’s modular architecture offers flexibility across various diseases and can be scaled efficiently in manufacturing. This scalability could significantly increase access to cell therapies, particularly for patients with rapidly progressing illnesses who may not have time for conventional treatments.
A New Era in Cell Therapy
Cindy Perettie, executive vice president of Kite, emphasized the potential of in vivo therapy to transform patient care. “In vivo therapy is a promising frontier with the potential to transform how we approach treating patients, shifting to more accessible and scalable solutions,” she stated. By combining Interius’s innovative platform with Kite’s extensive expertise in cell therapy research, development, and manufacturing, the company aims to accelerate the delivery of high-quality in vivo therapies to patients.
Following the acquisition, Interius’s staff and operations will be integrated into Kite’s research organization, forming a Philadelphia-based center of excellence focused on next-generation in vivo therapies. This centralized hub is expected to drive innovation and streamline the development of new treatments.
Phil Johnson, president and CEO of Interius BioTherapeutics, highlighted the significance of the deal. “This marks a pivotal step for Interius and the future of in vivo therapy, which has the potential to reduce treatment timelines, broaden access to care and improve outcomes for patients with aggressive or advanced disease,” he said. With Kite’s global infrastructure and deep expertise, Interius is well-positioned to expand into multiple therapeutic areas and deliver meaningful innovations to patients.
Financial Details and Next Steps
Under the terms of the agreement, Kite will acquire all outstanding shares of Interius for $350 million at closing, subject to customary adjustments. Gilead anticipates that the transaction will impact its 2025 GAAP and non-GAAP earnings per share by approximately $0.23 to $0.25. The deal is contingent upon the expiration or termination of the Hart-Scott-Rodino waiting period and other standard closing conditions.
TD Cowen has been appointed as the exclusive financial advisor to Kite, while Evercore is providing advisory services to Interius. This collaboration underscores the confidence both companies have in the future of in vivo therapy and the potential for transformative advancements in cancer treatment.
As Kite and Interius work together to advance their shared vision, the integration of in vivo CAR technology into mainstream cell therapy represents a major leap forward in the fight against serious diseases. This acquisition not only strengthens Kite’s position in the biotech industry but also paves the way for more efficient and effective treatment options for patients worldwide.





